UNASSIGNED: @entity6 is one of the risk factors for @entity195 . Our previous findings indicated that animals with @entity6 exhibit @entity73 in addition to @entity179 , both of which are ameliorated with @entity477 ( @entity477 ) 17-mer (APP17) peptide treatment. Although APP17 is neuroprotective, it is susceptible to enzymatic degradation. Derived from the active sequence structure of APP17, we have previously structurally transformed and modified several APP5-mer peptides (APP328-332 [RERMS], @entity477 5). We have developed seven different derivatives of APP5, including several analogs. Results from the @entity2454 assay on @entity1 @entity521 SH-SY5Y cells in the present study showed that P165 was the most neuroprotective APP5 derivative. Furthermore, we tested the effects of APP5 and P165 on the number of cells and the release of @entity880 dehydrogenase. Western immunoblot analyses were also performed. The digestion rates of P165 and APP5 were determined by the pepsin digestion test. P165 resisted pepsin digestion significantly more than APP5. Therefore, P165 may be optimal for oral administration. Overall, these findings suggest that P165 may be a potential drug for the treatment of @entity6 .

Neurotrophic effects of XXXX peptide 165 in vitro.

@entity1 :: ('9606', 'Species') :: ['human'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic encephalopathy', 'Diabetic encephalopathy'] @entity73 :: ('MESH:D003072', 'Disease') :: ['learning and memory impairment'] @entity477 :: ('351', 'Gene') :: ['APP', 'amyloid precursor protein'] @entity2454 :: ('MESH:C022616', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide'] @entity179 :: ('MESH:D019636', 'Disease') :: ['hippocampal neurodegeneration'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity521 :: ('MESH:D009447', 'Disease') :: ['neuroblastoma'] @entity195 :: ('MESH:D000544', 'Disease') :: ["Alzheimer's disease"]
@entity477 :: (351,Gene) :: ['amyloid precursor protein']
